Recently, ganetespib was found to suppress the expression of several immune checkpoint molecules including PD‐L1, PD‐L2, B7‐H3 and B7‐H4 in cancer cells due to the destabilisation of related transcription factors such STAT3, which is a client protein of HSP90.147. This evidence concerns the gene CD274 and cancer.